Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Vor Biopharma ( (VOR) ) just unveiled an announcement.
On May 22, 2025, Vor Biopharma Inc. held its annual meeting of stockholders where key decisions were made. The stockholders approved an amendment to double the authorized shares of common stock from 400 million to 800 million, potentially impacting the company’s capital structure and future financing capabilities. Additionally, Matthew Patterson and Daniella Beckman were elected as Class I Directors, and Ernst & Young LLP was ratified as the independent public accounting firm for 2025, reflecting continuity in leadership and financial oversight.
The most recent analyst rating on (VOR) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Underperform.
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Vor Biopharma Inc. operates in the biotechnology industry, focusing on the development of novel therapies for cancer treatment. The company is dedicated to advancing its proprietary platform to engineer hematopoietic stem cells to improve the efficacy of targeted therapies.
Average Trading Volume: 1,795,264
Technical Sentiment Signal: Sell
Current Market Cap: $23.34M
For detailed information about VOR stock, go to TipRanks’ Stock Analysis page.